Abciximab suppliers
Abciximab
- CAS:
- MF:
- MW:
- 0
Properties
Safety Information
Use
Abciximab (ReoPro, chimeric) is an MAb engineered from theglycoprotein IIb/IIIa receptor of human platelets. The preparationis fragmented, containing only the Fab portion of theantibody molecule. This MAb is a chimeric human–mouseimmunoglobulin. The Fab fragments may contain mouse variableheavy- and light-chain regions and human constantheavy- and light-chain regions.Abciximab is indicated as an adjunct to percutaneoustransluminal coronary angioplasty or atherectomy for theprevention of acute cardiac ischemic complications in patientsat high risk for abrupt closure of a treated coronaryvessel. Abciximab appears to decrease the incidence ofmyocardial infarction.Abciximab binds to the intact GPIIb/GPIIIa receptor,which is a member of the integrin family of adhesion receptorsand the major platelet-specific receptors involved in aggregation.The antibody prevents platelet aggregation bypreventing the binding of fibrinogen, the von Willebrandfactor, and other adhesion molecules on activated platelets.The inhibition of binding to the surface receptors may be aresult of steric hindrance or conformational effects preventinglarge molecules from approaching the receptor.
9 supplier list of "Abciximab"
- Product Name:Abciximab
- Company Type: Trader
- Country/Region: EUROPE
- Product Name:Abciximab
- Company Type: Trader
- Country/Region: EUROPE
- Product Name:Abciximab
- Company Type: Reagent
- Country/Region: INDIA
- Product Name:Abciximab
- Company Type: Reagent
- Country/Region: INDIA